Comparative Assessment of Drug Lag for Approved Oncology Targeted Therapies Between Saudi Arabia, the United States, and the European Union

• Published in: Therapeutic innovation & regulatory science Vol. 58; no. 4; pp. 678 - 686
• Main Authors: Alnuhait, Mohammed, Alshammari, Abdullah, Alharbi, Manar, AlOtaibi, Lina, Alharbi, Reem, Khobrani, Attiah, Alkhudair, Nora, Alshamrani, Majed, Alrajhi, Abdullah M.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2024; Springer Nature B.V
• Subjects: Availability; Cancer therapies; Drug Safety and Pharmacovigilance; Drugs; Evaluation; Global health; Health care; Medicine; Oncology; Original Research; Pharmaceutical industry; Pharmaceuticals; Pharmacology; Pharmacotherapy; Pharmacy; Public health; Toxicity; Saudi Arabia; United States > US; Targeted therapies; Regulatory; Oncology; Drug lag; Saudi arabia
• ISSN: 2168-4790; 2168-4804; 2168-4804
• DOI: 10.1007/s43441-024-00642-5

Introduction Pharmaceutical regulation on a global scale is a complex process, with regulatory bodies overseeing various aspects, including licensing, registration, manufacturing, marketing, and labeling. Among these, the USFDA plays a crucial role in upholding public health. The pharmaceutical industry contributes significantly to well-being by developing and distributing therapeutic agents. The journey of evaluating new pharmaceuticals involves meticulous examination through several phases, from safety and efficacy assessments to toxicity evaluation. Drug approval involves submitting New Drug Applications (NDAs) to regulatory agencies like the USFDA and EMA. However, disparities in durations contribute to the phenomenon known as “drug lag.” This lag refers to delays in a pharmaceutical product’s availability in one market compared to another. Addressing this issue is crucial, given its impact on patient access to treatments. Method This study aims to analyze the extent of drug lag, focusing on newly approved oncology targeted therapies in Saudi Arabia, the United States, and the European Union. Data for cancer treatments authorized by the USFDA, EMA, and SFDA from January 1, 1997, to December 31, 2022, were collected from regulatory agency websites. The data sources included authorization letters, prescription information, and evaluation documents. We conducted a comparative assessment of drug lag for approved oncology targeted therapies between Saudi Arabia, the US, and the EU. Result Our analysis identified 135 newly approved oncology-targeted drugs within the specified timeframe. Of these, 71 received approval in all three regions, while disparities were evident in others. The USFDA consistently had the highest number of approved drugs, with 98.5% of drugs initially approved there. In contrast, Saudi Arabia had the lowest number of approved drugs and a significantly longer median drug lag, indicating substantial delays in drug availability. Conclusion This study highlights the significance of mitigating drug lag to enhance global healthcare outcomes and patient access to innovative therapies. Further research and collaborative efforts are essential to bridging these disparities and promoting equitable healthcare worldwide.